|
Figure 3.
Figure 3. Characterisation of selected superantigen
variants. (a) Binding analysis of human anti-SEA to selected
superantigen variants using a scintillation proximity assay. In
more detail, human anti-SEA was labelled with 125I and the
direct binding of these antibodies to increasing concentrations
of C215FabSEA, C215FabSEA/E-18, -65, -97, -109, -110, -113 or
-120 on biotin conjugated anti-mouseF(ab)[2] on streptavidin PVT
beads was measured. (b) The ability to mediate T cell dependant
cytotoxicity on tumour cells by increasing concentrations of the
selected fusion proteins measured in a cytotoxicity assay
against Colo205 cells. (c) The ability of the constructs to
mediate T cell dependent killing of MHC class II expressing Raji
cells. The calculations are described in Materials and Methods.
In a clinical situation, the assay in (b) has been designed to
imitate the killing of tumor cells while the assay in (c)
reflects induction of systemic toxicity.
|
